# Healthcare Professionals Agree Cannabis Has "Legitimate Therapeutic Uses" > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/healthcare-professionals-agree-cannabis-has-legitimate-therapeutic-uses/ > **Published:** 2026-07-07T12:13:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:58:38-04:00 > **Clinical Summary:** Survey: 89% of healthcare professionals acknowledge cannabis has legitimate therapeutic uses. Clinical implications for practice. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchPolicyPainAnxietyMental HealthSafetyCBD Why This Matters Healthcare professionals increasingly recognize cannabis as having legitimate therapeutic applications, which may influence clinical decision-making for patients with conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), chemotherapy-induced nausea, and epilepsy where evidence supports efficacy. Clinicians need to understand evolving professional consensus on cannabis to provide informed counsel to patients who are asking about or considering [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), reducing information gaps that currently exist in clinical practice. This shift in professional opinion may facilitate more evidence-based conversations about cannabis as a potential treatment option rather than reflexive dismissal, improving patient safety by addressing use patterns that already occur outside clinical oversight. Clinical Summary A survey published in the Journal of [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) found broad consensus among US healthcare professionals that cannabis has legitimate therapeutic applications, supporting its integration into clinical practice. This agreement across diverse provider groups reflects growing evidence for cannabis efficacy in conditions such as [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), nausea, and certain seizure disorders, yet many clinicians report barriers to implementation including knowledge gaps, regulatory uncertainty, and limited clinical guidelines. The study highlights a disconnect between professional acceptance of cannabis’s therapeutic potential and actual prescribing or recommendation practices, suggesting that education and standardization of evidence-based protocols could facilitate wider clinical adoption. As more states legalize [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) and patient demand increases, this professional consensus provides important validation for clinicians considering cannabis as part of their treatment armamentarium. Clinicians should recognize this growing professional support as a signal to deepen their cannabis knowledge and develop evidence-based frameworks for patient counseling and monitoring when recommending cannabis for appropriate indications. Clinical Perspective 🏥 While growing professional consensus around cannabis’s therapeutic potential may encourage more clinicians to explore its clinical applications, this survey-based agreement should be interpreted cautiously given the substantial heterogeneity in training, evidence access, and practice settings across healthcare disciplines. The perceived legitimacy of cannabis as a therapeutic agent does not necessarily translate to robust evidence for specific clinical indications, dosing protocols, or patient populations, and clinicians must remain mindful that professional opinion can outpace the quality and quantity of rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). Important confounders include potential selection bias in survey respondents, variations in state-level legal frameworks that shape clinician attitudes regardless of evidence quality, and the possibility that enthusiasm reflects relative harm reduction compared to other substances rather than robust efficacy data. For practitioners considering cannabis in their practice, the practical implication is to view professional consensus as a signal to engage with the existing evidence base systematically, establish clear clinical criteria for use, and maintain robust 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Healthcare+Professionals+Agree+Cannabis+Has+%26quot%3BLegitimate+Therapeutic+Uses%26quot%3B+%40drcaplan&url=https%3A%2F%2Fnorml.org%2Fblog%2F2026%2F07%2F07%2Fsurvey-healthcare-professionals-overwhelmingly-agree-that-cannabis-has-legitimate-therapeutic-uses%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fnorml.org%2Fblog%2F2026%2F07%2F07%2Fsurvey-healthcare-professionals-overwhelmingly-agree-that-cannabis-has-legitimate-therapeutic-uses%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Healthcare+Professionals+Agree+Cannabis+Has+%26quot%3BLegitimate+Therapeutic+Uses%26quot%3B+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fnorml.org%2Fblog%2F2026%2F07%2F07%2Fsurvey-healthcare-professionals-overwhelmingly-agree-that-cannabis-has-legitimate-therapeutic-uses%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - In the Mix: 37 More Articles — June 20, 2026 - [In the Mix: 39 More Articles — June 16, 2026](https://cedclinic.com/39-cannabis-articles-clinical-relevance-june-16-2026/) - [CED Digest: 35 Items — April 09, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-april-2026-digest/) 📰 Source: [https://norml.org/blog/2026/07/07/survey-healthcare-professionals-overwhelmingly-agree-that-cannabis-has-legitimate-therapeutic-uses/](https://norml.org/blog/2026/07/07/survey-healthcare-professionals-overwhelmingly-agree-that-cannabis-has-legitimate-therapeutic-uses/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).